Clinical Trials
1 posts
Moderna and Merck's personalized mRNA cancer vaccine is the first to succeed in Phase 3. How neoantigens and Keytruda divide the work, what the numbers actually show, and what is still unanswered.
1 posts
Moderna and Merck's personalized mRNA cancer vaccine is the first to succeed in Phase 3. How neoantigens and Keytruda divide the work, what the numbers actually show, and what is still unanswered.